Chronic fatigue immune dysfunction syndrome (CFIDS) is a recently recognized illness characterized by debilitating fatigue as well as immunological and neurological abnormalities [Straus, S. E. (1988) J. Inf. Dis. 157, 405412]. Once thought to be caused by Epstein-Barr virus, it is now thought to have a different but unknown etiology. We evaluated 30 adult and pediatric CFIDS patients from six eastern states for the presence of human T-lymphotropic virus (HTLV) types I and II by Western immunoblotting, polymerase chain reaction, and in situ hybridization of blood samples. The majority of patients were positive for HTLV antibodies by Western blotting and for HTLV-II gag sequences by polymerase chain reaction and in situ hybridization. Twenty nonexposure healthy controls were negative in all assays. These data support an association between an HTLV-ll-like virus and CFIDS.
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The chronic fatigue immune dysfunction syndrome (CFIDS) is characterized by hematologic, neurologic, and neuromuscular abnormalities (1) (2) (3) (4) (5) . Once called chronic Epstein-Barr virus syndrome, this disease may be related or identical to myalgic encephalomyelitis, Iceland disease, and epidemic neuromyasthenia (6) .
Several immunologic abnormalities have been documented in CFIDS patients (7) (8) (9) (10) . These abnormal immune patterns may represent primary immunologic defects or appear secondary to chronic infection. Although several viruses have been associated with CFIDS, including herpesviruses (11) (12) (13) and enteroviruses (14) , the ubiquitous nature of these agents has hampered identification of any one as the etiologic agent. We examined adult and pediatric CFIDS patients for evidence of human retroviruses, human T-lymphotropic virus (HTLV) types I and II. For comparison, we also tested healthy age-and sex-matched controls who were household or casual contacts of these patients and healthy people who had no history of or exposure to CFIDS. All samples were coded and the investigators "blinded."
MATERIALS AND METHODS
Subjects. The first cohort consisted of 10 adults and 2 teenagers from a North Carolina referral practice drawn from six eastern states. All patients met established criteria for CFIDS (1) and 4 of the patients were severely affected and largely homebound. The second cohort consisted of 19 children (<18 years of age) from rural upstate New York, where they were part of a CFIDS epidemic in 1985 (15) . Of these 19 children, 13 with mild to moderate symptoms were clustered in four families. Six children were not from family clusters. Three of these had severe symptoms and were homebound for more than 6 months.
Healthy age-and sex-matched exposure controls were recruited from among people in North Carolina and New York who had either sexual or casual contacts with the patients. Blood samples from 20 healthy nonexposure controls were obtained in the Philadelphia area: 10 from adults and 10 from umbilical cords of newborns. All adult donors and mothers of newborns denied symptoms of CFIDS and exposure to CFIDS patients.
All patients and controls were Caucasian and denied histories of blood or gamma globulin transfusions, intravenous drug abuse, and male homosexuality. None of the pediatric patients was known to be sexually active and no evidence of sexual abuse was observed. Sera from all patients and controls were tested by the American Red Cross (Philadelphia) and found negative for human immunodeficiency virus (HIV) antibodies and hepatitis B antigen.
Patients' and exposure controls' heparinized blood samples were coded by the referral clinicians and the investigators were blinded. Each patient and exposure control was bled two or three times over 2 years, depending on patient consent. The nonexposure controls were processed and coded by a single person, who was not involved in the experiments. In all experiments, these control samples were interspersed with samples from patients and exposure controls.
Western Immunoblot. Serum or plasma was tested for antibodies to HTLV-I and -II by Western blotting (16) . Density gradient-purified HTLV-I from MT-2 cells was generously provided by V. Kalyanaraman mixture controls without DNA and with noninfected cellular DNA (U-937 monocytic cells) were included with every PCR.
Oligonucleotides were synthesized and HPLC-purified on a 5-15% acetonitrile gradient in 50 mM triethylamine/acetic acid, pH 7.0, by the Wistar DNA synthesis facility. Amplified DNA was stored at -20°C until use. The template capability of purified DNA was verified by performing a PCR using /3-globin primers (19 (17) at 37°C. The filters were exposed to Kodak XAR film for 5-7 days at -70°C.
In Situ Hybridization. Cells expressing RNA homologous to HTLV-I and HTLV-II were detected by in situ hybridization using 35S-labeled RNA antisense probes specific for the 5' region of both viruses. HTLV-I and HTLV-II gag subclones from MT-2 and Mo-T, respectively, were inserted into the pSP64 Sac I site and transcribed as reported (20) . The RNA transcripts averaged 0.5 kilobase in length and were hybridized at 1-2 x 108 dpm/ml at 50°C on 4% paraformaldehyde-fixed activated peripheral blood mononuclear cells (PBMCs). The cells were centrifuged onto glass slides and then autoradiographed for 4-8 days (16 (Fig. 2) .
The results of amplification and Southern blotting for HTLV-I gag are shown in Fig. 3 . Although a strong signal was observed from MT-2 DNA, all CFIDS patients and controls were negative. Identical results were observed using HTLV-I tax primers (data not shown).
In contrast, when the same samples were analyzed for an HTLV-II gag region, products of the appropriate size (identical to that in Mo-T) were seen in a majority of adult (Fig. 4A) and pediatric (Fig. 4B ) CFIDS patients. Several exposure controls in both cohorts were also found to contain the same HTLV-II gag region as CFIDS patients. These same primers did not amplify any hybridizable product from the blood of 10 healthy infants or 10 healthy adults (Fig. 4 C and D) . (Although shown here in a separate autoradiogram for illustration, these controls were routinely interspersed with patient samples and found negative when assayed.) Despite the lack of amplification of the HTLV-II gag region in the nonexposure controls, the DNA from these samples was a competent template for PCR, since a region of f3-globin was routinely amplified using specific primers (Fig. 4E) of DNA from Mo-T and was detected in only one exposure control (data not shown). The PCR experiments are summarized in Tables 1 and 2 .
Retroviral mRNA Detection. To determine whether the HTLV-II gag region amplified by PCR of patients' DNA was part of a functional gene, we evaluated the expression of HTLV mRNA in PBMCs by in situ hybridization using gag transcripts from both HTLV-I and -II. Fig. 5 shows the typical pattern of reactivity seen with HTLV-II gag RNA probe. The analysis of adult samples is summarized in Table 3 .
DISCUSSION
We have presented evidence for HTLV-II-like infection of blood cells from CFIDS patients and, to a lesser extent, from some people who closely associate with them. More than 50% of samples from 31 patients contained antibodies to at least two viral gene products by Western blot analysis. Since serologic assays using HTLV-I-derived antigens cannot distinguish between HTLV-I-and -II-specific antibodies, the positive Western blots may be directed toward either virus (21) . Because purified HTLV-I was used as the antigen, it is unlikely that the antibodies were detecting cellular antigens shed from the infected MT-2 cells. This is further substantiated by patient reactivity to proteins with the molecular weights reported for HTLV-I and -II antigens. The pronounced reactivity to gag (p19 and p24) and env (gp45-46) in The frequency of these antibodies in CFIDS patients compared with healthy, noncontact controls suggests exposure/infection with an HTLV-like agent rare in healthy noncontact people. Some adult CFIDS patients in the study were from the southeastern United States, where HTLV-I infections are more frequent, but the reported incidence of HTLV seropositivity in blood donors there is only 0.05% (22) . More important, the pediatric patients reside in rural upstate New York, where population studies have shown that the HTLV seropositivity rate approaches zero (22) .
Although polyclonal upregulation of antibodies to other viruses has been reported in CFIDS, this mechanism is unlikely with respect to HTLV (23) . These antibodies appear to be directed exclusively to viruses to which the majority of the population has been exposed. Polyclonal B-cell activation would not be expected to induce antibodies to a virus the patients had never encountered.
To detect the presence of proviral HTLV in blood cells of CFIDS patients, we amplified specific regions ofHTLV-I and HTLV-II by PCR. None of the CFIDS patients' blood samples contained detectable HTLV-I gag sequences. In contrast, DNA from at least two separate bleedings was positive for the HTLV-II gag subregion in 83% of adult and 72% of pediatric CFIDS patients. None of the HTLV regions examined was amplified from DNA of 20 nonexposure controls. If this gag gene is a segment of a complete provirus, the retrovirus is probably not prototypic HTLV-II (24), since we did not amplify an HTLV-II tax region in CFIDS patients that is found in Mo-T. The reported sequence variability among HTLV-II isolates, not seen with isolates of HTLV-I, supports this hypothesis (25) .
We confirmed these findings on the adult CFIDS samples by demonstrating that 7 out of 10 HTLV-II gag-positive samples by PCR had cells expressing HTLV-II gag mRNA. Moreover, the detection of viral mRNA in these cells dem- (20) .
The (26) . The correlation between the'presence of serum antibodies to HTLV and detectable' HTLV-II-like gag DNA or RNA in CFIDS patient blood was high but not universal. Of 13 pediatric patients positive by PCR, 10 were Western blotpositive. Of 10 adult PCR-positive patients, 5 had positive Western blots. The lower frequency of antibody-positivity in adults is compatible with the reported incidence of cellmediated anergy in adult CFIDS (27) . Alternatively, antibody-negative patients may reflect latency of the retroviruslike gene. In fact, of 6 Western blot-negative CFIDS adults, HTLV-II gag mRNA could not be detected in 4. Conversely, of 6 Western blot-positive adult patients, 5 expressed HTLV-II gag mRNA.
The clinical histories of these CFIDS patients do not reveal behavioral or genetic factors usually associated with retroviral infection. Yet our data suggest' that not only are these HTLV-II-like genes and HTLV-reactive antibodies associated with CFIDS in patients but that samples from a significant proportion of their nonsexual contacts are positive. Because this study was not designed to address the issue of transmissibility of the agent, conclusions regarding its communicability would be premature. However, the epidemiology of some CFIDS cases suggests horizontal, casual transmission, as in the epidemics at Lake Tahoe, Nevada (23) , and Lyndonville, New York (15) .'Herberman and colleagues (28) have reported that natural killer (NK) cell abnormalities found in CFIDS patients are observed in some healthy contacts of the patients, but not in healthy, nonexposure controls (28) .
Although our data support an association between an HTLV-like agent and CFIDS, we cannot, as yet, define the agent's role in the disease process. Rather than an etiologic agent, it may be a benign secondary infection to which immunologically compromised patients are susceptible. Alternatively, it may be one of two viruses that, when coinfecting the same hematopoetic cells, induce immune dysfunction. In any case, biological characterization of this agent and its role in the pathogenesis of CFIDS awaits its isolation.
